Welcome to our dedicated page for Inflarx SEC filings (Ticker: IFRX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Clinical-stage biotech filings can read like lab notebooks. InflaRx’s 10-K packs trial protocols, C5a immunology, and milestone payments into hundreds of pages—details vital if you’re gauging cash runway or FDA risk. Finding the right paragraph before the market moves is the problem investors face every quarter.
Stock Titan solves it. Our AI digests each InflaRx quarterly earnings report 10-Q filing, highlights burn-rate changes, and flags shelf-registration clauses—InflaRx SEC filings explained simply. Need real-time governance signals? Receive alerts the moment an InflaRx 8-K material events explained disclosure hits EDGAR. Curious whether management is buying? Track InflaRx Form 4 insider transactions real-time for swift reads on executive sentiment.
Here’s what you can explore today:
- InflaRx insider trading Form 4 transactions—spot patterns in officer purchases or sales.
- InflaRx annual report 10-K simplified—AI pinpoints trial milestones, cash reserves, and risk factors.
- InflaRx proxy statement executive compensation—understand incentive alignment without wading through tables.
- InflaRx earnings report filing analysis—compare enrollment progress quarter over quarter.
Whether you’re understanding InflaRx SEC documents with AI or following InflaRx executive stock transactions Form 4, Stock Titan’s expert layer provides the context—so you act on data, not on guesswork. Every filing, every update, delivered when it matters.
InflaRx N.V. (IFRX) reported preliminary, positive Phase 2a topline results for INF904, an oral C5aR inhibitor, in hidradenitis suppurativa (HS) and chronic spontaneous urticaria (CSU). The study evaluated safety and PK/PD with exploratory efficacy.
In HS (efficacy n=29 of 31; safety n=33), patients showed rapid, clinically meaningful reductions in abscesses and nodules and draining tunnels, improved pain (NRS30) and DLQI, and higher HiSCR at end of treatment that continued to deepen four weeks later. The company notes these 4‑week outcomes were largely in line with similar timepoint data from approved HS therapies. No serious adverse events were reported across doses (60, 90, 120 mg BID).
In CSU (efficacy n=30 of 31; safety n=33), the 60 mg BID cohort achieved a UAS7 change from baseline of -13.7 at week 4, exceeding average historically reported placebo levels and generally within the range of existing approved CSU drugs. Severe CSU at baseline saw a -15.4 UAS7 change; patients with angioedema at baseline saw -18.7. Improvements began by Week 1 and generally deepened over the four-week treatment period. No serious adverse events were reported.
FAQ
What is the current stock price of Inflarx (IFRX)?
What is the market cap of Inflarx (IFRX)?
